Loading...
Loading...
Baxalta Incorporated
BXLT, a global biopharmaceutical leader
dedicated to delivering transformative therapies to patients with orphan
diseases and underserved conditions, announced today that it has submitted
supplemental Biologics License Applications (sBLAs) to the U.S. Food and
Drug Administration (FDA) seeking approval for the use of ADYNOVATE
[Antihemophilic Factor (Recombinant), PEGylated] to treat children under the
age of 12 with hemophilia A and for use in surgical settings.
ADYNOVATE is the only extended circulating half-life recombinant Factor VIII
(rFVIII) treatment for hemophilia A based on the demonstrated efficacy of
ADVATE [Antihemophilic Factor (Recombinant)]. ADYNOVATE was approved by the
FDA in November 2015 for use in adolescent and adult hemophilia A patients
(12 years and older) for prophylaxis to reduce the frequency of bleeding
episodes and on-demand treatment and control of bleeding.
"We know there is a great need for innovative new treatments among pediatric
patients and during surgery and we look forward to working with the FDA as
they review ADYNOVATE for these patients," said Brian Goff, executive vice
president and president, Hematology. "We are committed to continually
advancing direct factor replacement treatments and specifically to expanding
use of ADYNOVATE, providing as many patients as possible access to its
proven prophylaxis and simple, twice-weekly dosing schedule."
The submission of ADYNOVATE to treat children under the age of 12 was based
on results of a Phase 3 trial designed to assess the efficacy and safety
including immunogenicity of ADYNOVATE, which was initially reported in
December 2015. Results from the study showed ADYNOVATE met its primary
endpoint and no patients developed inhibitory antibodies to ADYNOVATE. In
addition, no treatment-related serious adverse events were reported. More
than 70 percent (72.7 percent) of patients had no joint bleeds while on
treatment with ADYNOVATE (n=66) and nearly 40 percent (37.9 percent)
experienced zero bleeds. The median overall annualized bleeding rate (ABR)
among patient participants treated with ADYNOVATE was 2.0 (range 0-49.8;
mean ABR 3.0), which was comparable to the rates seen in the adult study.
The filing was also supported by the positive results of a Phase 3 study
evaluating the efficacy and safety of ADYNOVATE for the perioperative
control of hemostasis among 15 patients with severe hemophilia A undergoing
surgical procedures, which was reported in December 2015. The study data
demonstrated that ADYNOVATE achieved hemostasis control in the perioperative
period (from start of the procedure until discharge or day 14) for patients
with severe hemophilia A.
Baxalta continues to invest in ADYNOVATE to expand the product's value for
more patients worldwide. Baxalta plans to file for marketing authorization
in Europe in the first quarter of 2016 and expects regulatory approval of
the treatment in Japan in the first half of the year. ADYNOVATE is also
under regulatory review in Canada and Switzerland.
ADYNOVATE is built on the full-length ADVATE molecule, a leading treatment
for hemophilia A that been used by patients worldwide for more than 12
years. Through a collaboration with Nektar Therapeutics
NKTR,
ADYNOVATE leverages proprietary PEGylation technology designed to extend the
amount of FVIII available for use in the body. The technology was selected
because it maintains the integrity of the parent molecule (ADVATE) and
reduces the time at which the body clears ADYNOVATE, resulting in an
extended circulating half-life. This proprietary technology has been used
for more than 15 years in a number of approved medicines that treat chronic
or serious conditions.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in